

CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW

1. DEPRESSION	1
1.1 Medications for depression.....	2
1.1.1 Limitations of Current Therapies.....	3
1.2 Role of gene therapy	4
1.3 Probable advantages of Gene Therapy	5
1.4 Potential Pitfalls of Gene Therapy for Depression	6
1.5 Therapeutic Targets of Gene Therapy for Depression.....	8
1.6 Scientific research in last decade for depression	10
1.7 Vectors for the gene delivery.....	15
1.8 Non-viral vectors for gene therapy	16
1.9 Cationic liposomes for gene delivery	16
1.10 Basic principles of cationic lipid-mediated gene transfection	18
1.11 Formation of cationic lipoplexes	20
1.11.1 Driving force and DNA condensation during lipoplex formation.....	20
1.11.2 Lipoplex structures	20
1.11.3 Factors affecting phase behaviour	23
1.11.4 Characteristics of cationic lipid	23
1.11.5 Ionic strength and temperature	24
1.11.6 Helper lipid	24
1.11.7 DNA concentration (or lipid to DNA ratio or L/P ratio)	25
1.11.8 Zeta potential	25
1.12 Delivery of DNA to the central nervous system.....	26
1.12.1 Targeting lipoplex across BBB using systemic delivery	26
1.12.2 Intranasal delivery.....	34
References.....	37

CHAPTER 2: AIM AND OBJECTIVES

2.1 Objective of the proposed work.....	45
2.2 Hypothesis	45
2.3 Plan of work.....	45

CHAPTER 3: ANALYTICAL METHOD DEVELOPMENT

3. INTRODUCTION	47
3.1 DNA quantification by uv spectrometry.....	47
3.2 Nanodrop spectrophotometer.....	49
3.2.1 Method verification.....	48
3.3 Gel electrophoresis for cdna quantification.....	49
3.4 Analytical methods for lipid characterization.....	50
3.4.1 TNBS assay.....	50
3.5 Bradfords protein assay	51
3.6 Result and discussion.....	52
3.6.1 Nanodrop.....	52
3.6.2 Gel electrophoresis.....	54
3.6.3 TNBS assay.....	56
3.6.4 Bradford assay.....	58
References.....	59

CHAPTER 4: PLASMID ISOLATION AND LIPID SYNTHESIS

4 (A) Rationale for selection of p11 gene.....	60
4 (A).1 Properties of p11 cDNA and protein.....	61
4 (A).2 Rationale for selection of eGFP gene.....	65
4 (A).3 Plasmid elements.....	70
4 (A).4 Transformation of p11 cDNA	71
4 (A).5 Transformation of competent <i>E. coli</i> using calcium chloride	71
4 (A).6 Isolation and purification of plasmid	73
4 (A).7 Plasmid digestion	77
4 (B) Cationic lipids for lipoplex.....	80
4 (B).1 Use of BOC protected amino acids	81
4 (B).2 Synthesis of amino acid modified lipid.....	81
4 (B).3 TNBS assay	86
4 (B).4 Buffering capacity	87
4 (B).5 Gas chromatography.....	87
4 (B).5.1 Toxic effects of residual solvent.....	88

4 (B).5.2 Instrumentation.....	88
4 (B).5.3 Chromate condition	88
4 (B).5.4 Preparation of standard and sample.....	88
4 (B).5.5 Specifications of Headspace injector and GC conditions.....	88
4 (B).6 Result and discussion	89
4 (B).6.1 Synthesis of amino acid conjugated DOPE.....	89
4 (B).6.2 Buffering capacity	93
4 (B).6.3 TNBS assay	94
4 (B).6.4 Gas chromatography.....	96
References.....	99

CHAPTER 5: FORMULATION AND DEVELOPMENT

5. Introduction.....	103
5.1 Preparation of liposomes	104
5.1.2 Optimization of process parameters	105
5.1.3 Optimization of formulation parameters.....	106
5.2 Preparation of Lipoplex	108
5.2.1 Optimization of process parameters	108
5.3 Physicochemical characterization.....	108
5.3.1 Size and zeta potential measurements with dynamic light scattering.....	108
5.3.2 Cryo-Transmission Electron Microscopy (Cryo-TEM)	109
5.3.3 Complexation efficiency.....	109
5.3.4 UV spectrophotometric determination.....	110
5.4 Stability challenge studies	110
5.4.1 Electrolyte induced flocculation study	110
5.4.2 Heparin polyanion competition assay.....	111
5.4.3 Serum stability study	111
5.5 Biocompatibility studies	111
5.5.1 Haemolysis study.....	111
5.5.2 Erythrocyte aggregation study.....	112
5.6 <i>In vitro</i> cell line studies.....	112
5.6.1 MTT assay	113
5.6.2 Cellular uptake study	115
5.6.3 Cell permeation study	116

5.6.4 Western blot analysis	118
5.6.5 <i>In vitro</i> gene expression study by Real time PCR (RT-PCR).....	122
5.7 Result and discussion.....	125
5.7.1 Formulation optimization using DOE.....	126
5.7.2 Statistical analysis Response 1 (particle size).....	128
5.7.3 Statistical Analysis of Response 2 (Polydispersity Index-PDI).....	140
5.7.4 Selection of Formulation Parameters.....	149
5.7.5 Point Prediction and Confirmation	152
5.7.6 Complexation efficiency and optimization of process parameters for complexation.....	154
5.7.7 Electrolyte induced flocculation study	159
5.7.8 Heparin polyanion competition assay.....	160
5.7.9 Serum stability study	161
5.7.10 Haemolysis study.....	163
5.7.11 Erythrocyte aggregation study.....	165
5.7.12 MTT assay	166
5.7.13 Cellular uptake study	167
5.7.14 Cell permeation study	169
5.7.15 Western blot analysis.....	170
5.7.16 RT-PCR	171
References.....	173

CHAPTER 6: ANIMAL STUDIES

6. Introduction.....	177
6.1 Nasal delivery of lipoplex.....	177
6.2 Formulation of nasal spray	178
6.2.1 Role of nasal spray ingredients.....	178
6.3 Characterization of nasal spray.....	179
6.3.1 Formulation parameters	179
6.3.2 Actuation parameters	180
6.4 Ex- vivo characterisation	182
6.4.1 Preparation of nasal mucosa membranes.....	182
6.4.2 <i>Ex vivo</i> permeation studies	182
6.4.3 <i>Ex vivo</i> nasal toxicity study	183

6.5 Systemic delivery of antibody-directed liposomes.....	183
6.6 Functionalisation of liposomes	187
6.6.1 Quantification of sulfhydryl groups.....	187
6.7 Preparation of immunoliposomes	188
6.7.1 Characterization of immunoliposomes (il)	189
6.7.2 Bradford's method for estimation of mab conjugation.....	191
6.8 Cell cytotoxicity and cellular uptake study of il.....	192
6.9 <i>In vivo</i> experiments.....	192
6.10 Intravenous acute toxicity studies.....	192
6.11 Transport across the nasal epithelia.....	197
6.12 Brain distribution study	197
6.14 Animal model for depression.....	198
6.14.1 Interferon α 2b (inf α 2b/ interferon) induced animal models	198
6.15 Western blot studies.....	199
6.16 Result and discussion.....	202
6.16.1 Formulation parameters for nasal spray.....	202
6.16.2 Actuation parameters for nasal spray.....	202
6.16.3 Ex- vivo nasal permeation study.....	207
6.16.4 Assessment of local toxicity on nasal mucosa.....	208
6.16.5 Functionalisation of liposomes	210
6.16.6 Quantification of sulfhydryl group	210
6.16.7 Characterization of immunoliposomes	211
6.16.8 Cell cytotoxicity and cell uptake study.....	214
6.16.9 Intravenous acute toxicity study	218
6.16.10 Transport across nasal mucosa	221
6.16.11 Brain distribution study	222
6.16.12 Animal model for depression.....	224
6.16.13 Western blot.....	225
6.16.14 RT-PCR studies	226
References.....	228

CHAPTER 7 :SUMMARY AND CONCLUSION